Table 1.
Characteristic of BLCA stage 0-I patients (n = 836).
| Variable | Statins Use of Patients (%) | p-Value | |
|---|---|---|---|
| Statin (+) (n = 313) |
Statin (−) (n = 523) |
||
| Age, Mean (SD) | 69.6 (12.6) | 68.4 (14.0) | 0.22 |
| Gender | 0.42 | ||
| Male | 236 (75.4) | 407 (77.8) | |
| Female | 77 (24.6) | 116 (22.2) | |
| T category | 0.53 | ||
| T1 | 313 (100.0) | 521 (99.6) | |
| T2 | 0 (0.0) | 2 (0.4) | |
| N category | - | ||
| N0 | 313 (100.0) | 523 (100.0) | |
| Cell type | 0.0017 | ||
| Urothelial carcinoma | 296 (94.6) | 455 (87.0) | |
| Adenocarcinoma, Squamous carcinoma, Neuroendocrine carcinoma | 3 (1.0) | 7 (1.3) | |
| Others | 14 (4.5) | 61 (11.7) | |
| BMI, kg/m | <0.0001 | ||
| <25 | 167 (53.4) | 381 (72.8) | |
| ≥25 | 146 (46.6) | 142 (27.2) | |
| CCI | <0.0001 | ||
| 0 | 142 (45.4) | 410 (78.4) | |
| 1–2 | 92 (29.4) | 74 (14.1) | |
| 3+ | 79 (25.2) | 39 (7.5) | |
| Lipid profiles, mg/dL | |||
| Total Cholesterol, mg/dL | 206.9 (44.8) | 182.3 (33.5) | <0.0001 |
| Normal or low (<200) | 82 (26.2) | 59 (11.3) | |
| High (≥200) | 105 (33.5) | 26 (5.0) | |
Abbreviation: BMI body mass index, CCI Charlson Comorbidity Index, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SD standard deviation.